Syntara Ltd - SNT share price
About Syntara Ltd
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Try Veye Free for 7 Days
Expert ASX stock picks, in-depth research & buy/sell signals — free for a full week.
No credit card required
Price Chart (SNT)
TOP ASX STOCKS Worth Watching
- ✓ Instant Access
- ✓ No Credit Card Required
- ✓ Free to join · No spam
Free to join · No spam · Unsubscribe anytime
By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.
Discover the Top ASX Stocks to Invest in 2026!
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Latest Article
